Search research articles
Contact Us
Filters
Showing results (1-10 of 80) with videos related to
Page
of 8
Sort By:
Cell Death & Disease
|
March 27, 2015
Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice
W Y So, Q Cheng, A Xu, et al.
Current Molecular Medicine
|
September 24, 2016
Calcitriol Reduces Hepatic Triglyceride Accumulation and Glucose Output Through Ca2+/CaMKKβ/AMPK Activation Under Insulin-Resistant Conditions in Type 2 Diabetes Mellitus
S Cheng, W Y So, D Zhang, et al.
Postgraduate Medical Journal
|
March 15, 2000
Gynaecomastia as a presenting feature of thyrotoxicosis
W B Chan, V T Yeung, C C Chow, et al.
International Journal of Clinical Practice
|
October 8, 2003
Hyperkalaemia in a patient with Graves' disease
C W Ng, N N Chan, W Y So, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
May 4, 2000
Genetics of type 2 diabetes mellitus
W Y So, M C Ng, S C Lee, et al.
Cost Effectiveness and Resource Allocation : C/E
|
July 16, 2019
Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis
E Lau, A Salem, J C N Chan, et al.
Kidney International
|
February 19, 2010
Development and validation of equations estimating glomerular filtration rates in Chinese patients with type 2 diabetes
Tak-Kei Leung, Andrea O Y Luk, W-Y So, et al.
International Journal of Clinical Practice
|
April 16, 1998
TSH secreting pituitary adenoma: a rare cause of thyrotoxicosis
W Y So, V T Yeung, C C Chow, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
January 1, 1996
Comparisons of Y-set disconnect system (Ultraset) versus conventional spike system in uremic patients on CAPD: outcome and cost analysis
P K Li, T H Chan, W Y So, et al.
Diabetes, Obesity & Metabolism
|
December 17, 2011
Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings--what, why and how?
X L Yang, R C W Ma, W-Y So, et al.
Page
of 8
Search research articles
Search
Showing results (1-10 of 80) with videos related to
Sort By:
Page
of 8
Cell Death & Disease
|
March 27, 2015
Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice
W Y So, Q Cheng, A Xu, et al.
Current Molecular Medicine
|
September 24, 2016
Calcitriol Reduces Hepatic Triglyceride Accumulation and Glucose Output Through Ca2+/CaMKKβ/AMPK Activation Under Insulin-Resistant Conditions in Type 2 Diabetes Mellitus
S Cheng, W Y So, D Zhang, et al.
Postgraduate Medical Journal
|
March 15, 2000
Gynaecomastia as a presenting feature of thyrotoxicosis
W B Chan, V T Yeung, C C Chow, et al.
International Journal of Clinical Practice
|
October 8, 2003
Hyperkalaemia in a patient with Graves' disease
C W Ng, N N Chan, W Y So, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|
May 4, 2000
Genetics of type 2 diabetes mellitus
W Y So, M C Ng, S C Lee, et al.
Cost Effectiveness and Resource Allocation : C/E
|
July 16, 2019
Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis
E Lau, A Salem, J C N Chan, et al.
Kidney International
|
February 19, 2010
Development and validation of equations estimating glomerular filtration rates in Chinese patients with type 2 diabetes
Tak-Kei Leung, Andrea O Y Luk, W-Y So, et al.
International Journal of Clinical Practice
|
April 16, 1998
TSH secreting pituitary adenoma: a rare cause of thyrotoxicosis
W Y So, V T Yeung, C C Chow, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
January 1, 1996
Comparisons of Y-set disconnect system (Ultraset) versus conventional spike system in uremic patients on CAPD: outcome and cost analysis
P K Li, T H Chan, W Y So, et al.
Diabetes, Obesity & Metabolism
|
December 17, 2011
Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings--what, why and how?
X L Yang, R C W Ma, W-Y So, et al.
Page
of 8